3rd Annual Symposium: Innovations in anti-mycobacterial Drug Discovery

Mycobacteria can be separated into tuberculosis (TB) causing mycobacteria (Mycobacterium tuberculosis, Mtb), leprotic mycobacteria, and non-tuberculous mycobacteria (NTM). Approximately one quarter of the World’s population is infected with Mtb in latent form. TB is of enhanced concern when combined with other diseases, such as HIV and Covid-19. Similar concerns hold true for NTM infections, which are increasing in their prevalence, morbidity and mortality and frequently surpass the global incidence of TB. NTM most commonly cause pulmonary infections, especially among patients with structural airway disease like cystic fibrosis and bronchiectasis, but can also cause lymphadenitis, skin and soft tissue infection, cardiac infection, bone and joint infections, and disseminated disease. Chemotherapy is long and often toxic, includes parenteral drugs, and suffers from poor cure rates.

The 3rd Annual Symposium: Innovations in anti-mycobacterial Drug Discovery will include presentations from speakers from around the world who have made significant advances in TB- and NTM research and –drug discovery. The goal of this event is to present novel concepts and to provide a platform for vibrant and open discussions between industry, senior scientists, postdoctoral fellows and students from academia.